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a  b  s  t  r  a  c  t
Rodent  defense  behavior  assays  have  been  widely  used  as preclinical  models  of  anxiety  to  study  possi-
bly  therapeutic  anxiety-reducing  interventions.  However,  some  proposed  anxiety-modulating  factors  –
genes, drugs  and  stressors  – have  had  discordant  effects  across  different  studies.  To  reconcile  the  effect
sizes  of  purported  anxiety  factors,  we  conducted  systematic  review  and meta-analyses  of  the literature
on ten  anxiety-linked  interventions,  as examined  in  the  elevated  plus  maze,  open  ﬁeld  and  light-dark  box
assays.  Diazepam,  5-HT1A  receptor  gene  knockout  and  overexpression,  SERT  gene  knockout  and  over-
expression,  pain,  restraint,  social  isolation,  corticotropin-releasing  hormone  and  Crhr1  were  selected  for
review.  Eight  interventions  had  statistically  signiﬁcant  effects  on  rodent  anxiety,  while  Htr1a  overexpres-
sion  and  Crh knockout  did  not.  Evidence  for publication  bias  was  found  in the  diazepam,  Htt  knockout,
and  social  isolation  literatures.  The  Htr1a  and  Crhr1  results  indicate  a disconnect  between preclinical






effects  were  paradoxical  in the  context  of the clinical  use  of SERT  inhibitors  to  reduce  anxiety.
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. Introduction
The anxiety disorders are among the costliest classes of men-
al disorders, with regard to both morbidity and economic cost
Baldwin et al., 2014; DiLuca and Olesen, 2014). Development of
nxiety-reducing (anxiolytic) drugs has been a major focus of the
harmaceutical industry and academic neuropsychiatric research,
hough no new drug types have been adopted since the intro-
uction of selective serotonin uptake inhibitors (SSRIs) and other
ntidepressants for the treatment of anxiety disorders (Griebel and
olmes, 2013; Tone, 2009). Anxiety research relies on similari-
ies between human emotional behavior and behaviors in animals
Darwin, 1998), speciﬁcally rat and mouse (Prut and Belzung, 2003).
hile there are many rodent behavioral paradigms that aim to
odel anxious behavior, three anxiety-related defense behavior
ARDEB) assays that speciﬁcally aim to measure rodent anxiety
ave been widely adopted, also referred to as ‘approach-avoidance
onﬂict tests’: the elevated plus maze (EPM), the light-dark box (LD)
nd the open ﬁeld (OF), the ﬁrst, second and ﬁfth most widely used
odent anxiety assays, respectively (Griebel and Holmes, 2013). All
hree assays use an arena that contains a sheltered domain (e.g., the
losed arms in EPM) and an exposed region. It is believed that an
nimal’s avoidance of the exposed portions of the chamber reports
n anxiety-like brain states. The ARDEB assays are accepted as pre-
linical assays of anxiety disorders, by reference to classic studies
hat tested their predictive validity with panels of drugs known to
ave anxiety-modulating effects in humans (Crawley and Goodwin,
980; Pellow et al., 1985; Simon et al., 1994).
Rodent research has been implicated in the largely frustrated
fforts to develop new types of anxiolytics (Griebel and Holmes,
013). The literature regarding defense behaviors is contradic-
ory about the size and even the direction of many interventions
hat are proposed to be anxiolytic or anxiogenic (together ‘anx-
otropic’) (Griebel and Holmes, 2013; Prut and Belzung, 2003). This
s true even for some anxiety-related factors with major clinical
elevance, such as the serotonin transporter (SERT/Htt),  the target
f the SSRIs. As with the assessment of clinical anxiety interven-
ions (Baldwin et al., 2014), a solid preclinical evidence base is
ecessary to guide decisions about further research and therapeu-
ic development (Vesterinen et al., 2014). To better understand the
idespread discordance in rodent anxiety studies, we conducted
 quantitative review of the effect of purported anxiety factors on
odent ARDEB. The primary aim of this study was  to examine the
elevance of these factors and to estimate the magnitude of their . . .  . . .  . . .  . .  .  . . . .  . . .  . .  . . .  . . . . .  . . . . .  .  . .  .  . . . .  .  . .  . . .  .  .  .  . .  . . . . .  . . . . .  .  .  .  .  . .  .  .  .  .  .  . 522
effects on rodent anxiety. A secondary goal of this analysis was
to examine patterns in ARDEB factor evidence: gaps in the litera-
ture, the extent of standardization/heterogeneity and publication
bias. Synthesizing the data on anxiety-targeted interventions might
also assist in understanding why  these assays have not led to new
therapies. Once conﬁrmed by meta-analysis, effective anxiotropic
interventions can be adopted as benchmarks against which to vali-
date new rodent assays and/or more tractable model animal species
(e.g. Drosophila and zebraﬁsh).
2. Materials and methods
2.1. Literature review
We identiﬁed genes, drugs and environmental interventions
that had been proposed to be involved in anxiety with a litera-
ture search of anxiety review articles. From two histories of anxiety
research (Griebel and Holmes, 2013; Tone, 2009), a list of ten anx-
iotropic interventions were chosen to be included in the systematic
review, either due to their clinical relevance (e.g., diazepam, Htt),
their role as an example of a class of proposed anxiety-related
factors (e.g., isolation), or their connection to possible forthcom-
ing therapeutics (e.g. Crh). A systematic review was conducted to
identify published articles addressing experimental outcomes in
rodents from the EPM, OF, or LD assays for these interventions
(Fig. 1). The literature for each genetic, pharmacological or envi-
ronmental intervention was identiﬁed by a search of PubMed and
EMBASE using speciﬁc search phrases (Table 1). The selective sero-
tonin reuptake inhibitors (SSRIs), which have clinical importance
(Baldwin et al., 2014), a very large number of studies conducted on
them (Griebel and Holmes, 2013), and controversial efﬁcacy (Kirsch
et al., 2008) are the subject of a separate meta-analytic study, cur-
rently in preparation.
2.2. Eligibility criteria and study selection
The search phrases in Table 1 were used to identify lists of stud-
ies. We  exported the articles’ bibliographic data (including study
ID, date of publication, title and abstract) of to a spreadsheet. Each
article on this list was  then reviewed at one or more of four levels
of detail (title, abstract, full text and a detailed review of experi-
mental design) to determine their eligibility for the review. Studies
were required to be written in English and to have reported ARDEB
in adult rats or mice. We  required that each included study contain
506 F. Mohammad et al. / Neuroscience and Biobehavioral Reviews 68 (2016) 504–529
Table  1
Summary of systematic reviews of anxiety-related interventions in mouse and rat. The PubMed and Embase query phrases used to identify articles that might contain data
relevant to the interventions and assays of interest are detailed. Title, abstract and full-text searches were performed to identify articles meeting the selected criteria.
Intervention Query phrase used in PubMed and Embase for study selection Articles identiﬁed by phrase Articles meeting
meta-analysis
criteria
Diazepam (diazepam OR valium) AND anxiety AND (open ﬁeld OR exploratory) AND
(rodent OR rat OR rats OR mouse OR mice OR Mus)
540 172
Ht1a  knockout (serotonin1A receptor OR 5-HT1A receptor) AND knockout AND anxiety 85 12
Ht1a  over-expression (serotonin1A receptor OR 5-HT1A receptor) AND (overexpression OR
over-expression OR overexpressing) AND anxiety
13 3
Htt  knockout (serotonin transporter) AND (knockout OR knockdown OR deletion OR
antisense) AND anxiety AND (elevated plus maze OR open ﬁeld OR light-dark)
AND (rats OR rat OR mice OR mouse OR Mus)
37 13
Htt  over-expression serotonin transporter AND anxiety AND (elevated plus maze OR open ﬁeld OR
light-dark) AND (increased OR over-expression OR overexpressing OR
transgenic) AND (rats OR rat OR mice OR mouse OR Mus)
65 2
Crh  knockout ((corticotropin-releasing) AND (stress-induced behaviors OR stress-related
behaviors or Behavioral responses to stress OR Behavioral responses to stress))
AND (CRH-deﬁcient mice OR lacking the CRH gene OR CRFko)
12 2
Crhr1 knockout (corticotropin releasing factor receptor 1-deﬁcient mice) OR CRH1 receptor
antisense oligodeoxynucleotide OR Crhr1 null mutants OR
Corticotropin-releasing hormone receptor antisense
62 6
Pain  (inﬂammatory pain OR neuropathic pain) AND anxiety AND (elevated plus
maze OR open ﬁeld OR light-dark) AND (rats OR rat OR mice OR mouse OR
Mus)
73 7
Restraint acute restraint AND anxiety AND (elevated plus maze OR open ﬁeld OR
light-dark) AND (rats OR rat OR mice OR mouse OR Mus)
87 15
Isolation (social isolation OR single housing) AND anxiety AND (elev
plus-maze OR open ﬁeld OR OFT OR light-dark) AND (rats O
mouse OR Mus)
1169 articles identified in PubMed and 
Embase searches for 10 anxiety related 
interventions using the search phrases 
given in Table1
671 articles included 
Title Sc reen
Abstract Screen





306 articles included in meta-analyses
Fig. 1. Flow chart of the systematic literature review of 10 anxiotropic interventions.
The  literature was reviewed in a four-stage process, starting with searches of the
Pubmed and EMBASE databases that yielded 1169 articles, followed by three screens











fesign. A total of 306 articles were used in the meta-analysis. Further details are
iven in Table 1 and the Methods section.
1) primary behavior data from either an OF, EPM, or LD experi-
ent for at least one of the interventions of interest, (2) suitable
ontrol data and (3) the relevant statistics (mean, standard error
r standard deviation, and sample sizes of both control and inter-
ention groups). Experiments that used combination treatments
ere excluded. Only studies in which adult rodents were assayed
ere included. For gene knockout and overexpression interven-
ions, we included only experiments that used a lifetime loss of
unction throughout the entire animal. All eligible experimentsated plus maze OR
R rat OR mice OR
167 50
from all eligible studies were included in the ten meta-analyses
(Table 1).
2.3. Data items and extraction
The following data were collected from each of the included
studies: authors, year of publication, ﬁgure and panel numbers,
species, genotype, and mean, standard error of the mean and sam-
ple size (N) of each intervention and its related control group.
Graphically presented data were extracted from Portable Docu-
ment Format (PDF) ﬁles with the Measuring Tool in Adobe Acrobat
Pro. All extracted data were checked by a second researcher. For
values extracted from tables, the check consisted of ensuring the
values were identical. For values extracted from graphical data
(e.g. bar plots), the check consisted of a visual inspection to ensure
that the extracted value matched the graphical data. Extraction
discrepancies were reconciled by conference between the primary
extractor and the researcher who identiﬁed the discrepancy.
2.4. Summary measures
The following behavioral metrics were extracted from the arti-
cles: in OF studies, percent or total time spent at the center; in
EPM studies, percent or total time spent on the open arm; in LD
studies, percent or total time spent in the bright area. To synthe-
size these time-based metrics from the three assays, all estimates
were standardized to Hedges’ g, a preferred variant of Cohen’s d
that uses the pooled standard deviation and is corrected for bias
using Hedges’ method (Borenstein et al., 2011; Cumming, 2012).
The conventional adjectives to describe effect size – trivial, small,
moderate, large – are used for effect sizes g < 0.2, g < 0.5, g < 0.8 and
g > 0.8 SD respectively (Cumming, 2012).
2.5. Synthesis of resultsMeta-analyses of experimental outcomes, including the calcu-
lation of weighted mean effect sizes (Hedges’g), 95% conﬁdence
intervals, I2 heterogeneity values, and P values using the random



















































Fig. 2. Funnel plots of three meta-analyses with evidence for publication bias.
Where at least ten experiments were available for meta-analysis, the effect sizes
(Hedges’g) of the experiments are plotted against their respective standard errors.
Points on each plot represent individual experiments. The triangle bounded by dot-F. Mohammad et al. / Neuroscience an
ffects model, were performed with the metafor package in R
http://CRAN.R-project.org/package=metafor) (Viechtbauer, 2010).
ll error bars in forest plots are 95% conﬁdence intervals; forest
lots were generated with custom R scripts.
.6. Assessment of bias across studies
Publication bias was assessed with funnel plots and Egger’s lin-
ar regression test of funnel plot asymmetry (Egger et al., 1997). The
tandard normal deviate (Hedges’g/standard error) for each study
as regressed against the study’s precision (1/standard error) using
he “lm” function in R (http://www.R-project.org/). For studies that
howed publication bias (P-value ≤ 0.05), the trim-and-ﬁll method
Duval and Tweedie, 2000) was employed to estimate the effects of
ublication bias on the effect size estimate. Funnel plots and trim-
nd-ﬁll adjustments were performed with the ‘metafor’ package in
 (Viechtbauer, 2010).
. Results
.1. Review selection criteria identiﬁed 306 eligible articles
The ﬂow-chart in Fig. 1 summarizes the study selection pro-
ess. In total, 1169 articles were identiﬁed by the initial search in
ubMed and EMBASE databases. According to the selection criteria
escribed above, 498 studies were excluded based on their titles
nd a further 150 were excluded based on their abstracts. The full
ext of the remaining 521 articles were screened for criteria related
o experimental paradigm, methods, and relevant variables, result-
ng in the exclusion of a further 215 studies. A total of 306 articles
ere considered eligible for inclusion in the review.
.2. Characteristics of included experiments
The characteristics of all included studies are given in Sup-
lementary Table 1. In brief, 582 experiments from 306 studies
omprising 411 EPM experiments, 84 OF experiments and 87
D experiments were identiﬁed. Studies were published between
985 and 2015 and included data from 318 experiments conducted
n mice and 264 experiments on rats. Studies reported 515 experi-
ents conducted on male animals, 29 on female, 35 on mixed and 3
xperiments with no gender information reported. ARDEB studies
f diazepam used a median dosage of 1 mg/kg, with minimum and
aximum dosages of 0.01 mg/kg and 20 mg/kg respectively, a dose
ange is similar to or higher than commonly used by patients.
.3. Heterogeneity
Statistically signiﬁcant heterogeneity was found in (8/10) of
he meta-analyses. Only two meta-analyses had high heterogene-
ty, I2 > 75%: Htr1a overexpression, and physical restraint (Higgins
t al., 2003). Three of the meta-analyses, pain and Htt knockouts
nd diazepam, had moderate heterogeneity (50% < I2 < 75%). Five
eta-analyses had low heterogeneity (I2 < 50%). As most of these
yntheses contained data from more than one assay type, it is
ncouraging that half had low or moderate heterogeneity, and out-
ome that is compatible with the idea that the three ARDEB assays
re testing similar aspects of rodent anxiety.
.4. Substantial publication bias in four anxiety factors
Censorship of non-statistically signiﬁcant experimental results
nd selective publication of statistically signiﬁcant ‘positive’ results
an cause a literature (and meta-analysis thereof) to overstate
ffect sizes. This effect, termed ‘publication bias,’ has a profound
nﬂuence on the literature on rodent models of stroke, and mayted lines indicates the area where 95% of studies are expected to fall, in the absence
of  both publication bias and study heterogeneity. Shown here are funnel plots for
experiments on (A) diazepam, (B) social isolation, -–and (C) Htt knockout.
affect other animal models (Sena et al., 2010). Publication bias in
the ARDEB literature was assessed for the six meta-analyses that
had at least 20 experiments (Table 2) (Sterne et al., 2011). Fun-
nel plots of these data showed pronounced asymmetry (Fig. 2),
which pointed to publication bias in these literatures (Sterne et al.,
2011). Egger’s asymmetry test indicated that four of these litera-
tures showed statistically signiﬁcant bias (Table 2). For the biased
data sets, we applied trim-and-ﬁll adjustment to estimate the num-
ber of hypothesized missing studies and to correct the bias (Duval
and Tweedie, 2000) (Fig. 2). These data support the idea that the
literatures of diazepam, Htt knockout, social isolation and restraint
effects on ARDEB are strongly affected by publication bias.
3.5. Diazepam reduces anxiety-related defense behaviors
Diazepam is an important minor tranquilizer that was used
for decades as the ﬁrst line of treatment for anxiety disorders
(Tone, 2009) and, along with other benzodiazepines, is still used
extensively to control anxiety (Baldwin et al., 2014). Recent clin-
ical meta-analysis studies have found support for the efﬁcacy of
benzodiazepines in the short-term treatment of anxiety disor-
ders (Baldwin et al., 2014). However, a review of diazepam effects
in open ﬁeld studies revealed widespread disagreement between
with 29 studies supporting an anxiolytic effect and 23 supporting
either an anxiogenic effect or no effect (Prut and Belzung, 2003).
We reviewed the available literature on diazepam for the three
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Assay = EPM
Gonzalez−Trujano ME   2012   Mice   0.01mg/kg   Male
Gonzalez−Trujano ME   2012   Mice   0.03mg/kg   Male
Gonzalez−Trujano ME   2015   Mice   0.1mg/kg   Male
Leggio   2011   Mice   0.1mg/kg   Male
Gonzalez−Trujano ME   2012   Mice   0.1mg/kg   Male
Harada K   2006   Rats   0.1mg/kg   Male
Griebel G   1999   Rats   0.1mg/kg   Male
Ponten   2011   Mice   0.1mg/kg   Male
Leggio   2011   Mice   0.1mg/kg   Male
Leggio   2011   Mice   0.1mg/kg   Male
Leggio   2011   Mice   0.1mg/kg   Male
Jones GH   1994   Mice   0.2mg/kg   Male
Satyan   1998   Rats   0.25mg/kg   Female and Male
Ene HM   2015   Mice   0.25mg/kg   Male
Ramanathan M   1998   Rats   0.25mg/kg   Female and Male
Griebel G   1998   Rats   0.25mg/kg   Male
Yasumatsu H   1994   Rats   0.25mg/kg   Male
Gonzalez−Trujano ME   2012   Mice   0.3mg/kg   Male
Wolfman C   1994   Mice   0.3mg/kg   Male
Assi.. MB   1993   Mice   0.3mg/kg   Male
Griebel G   1999   Rats   0.3mg/kg   Male
Dunn   1998   Rats   0.3mg/kg   Male
Harada K   2006   Rats   0.32mg/kg   Male
Jones GH   1994   Mice   0.39mg/kg   Male
Brioni   1994   Rats   0.484mg/kg   Male
Mahendra P   2011   Mice   0.5mg/kg   Male
Leggio   2011   Mice   0.5mg/kg   Male
Leggio   2011   Mice   0.5mg/kg   Male
Leggio   2011   Mice   0.5mg/kg   Male
Ramanathan M   1998   Rats   0.5mg/kg   Female and Male
Ognibene E   2008   Mice   0.5mg/kg   Male
Ene HM   2015   Mice   0.5mg/kg   Male
Srinivasan J   2003   Rats   0.5mg/kg   Male
Ponten   2011   Mice   0.5mg/kg   Male
Peng WH   2004   Mice   0.5mg/kg   Male
Yasumatsu H   1994   Rats   0.5mg/kg   Male
Yamada K   2000   Mice   0.5mg/kg   Not specified
Drapier D   2007   Rats   0.5mg/kg   Male
Mesfin M   2014   Mice   0.5mg/kg   Male
Lepicard EM   2000   Mice   0.5mg/kg   Male
Lepicard EM   2000   Mice   0.5mg/kg   Male
Griebel G   1999   Rats   0.5mg/kg   Male
Rochford J   1997   Mice   0.5mg/kg   Male
Fraser LM   2010   Mice   0.5mg/kg   Female and Male
Sakaue M1   2003   Mice   0.5mg/kg   Male
Jain   2005   Rats   0.5mg/kg   Male
Griebel G   1998   Rats   0.5mg/kg   Male
Leggio   2011   Mice   0.5mg/kg   Male
Wolfman C   1994   Mice   0.6mg/kg   Male
Baretta IP   2012   Mice   0.75mg/kg   Male
Tolardo R   2010   Mice   0.75mg/kg   Male
Da Silva NL   1996   Rats   0.75mg/kg   Male
R..go L   1988   Mice   0.75mg/kg   Male
Da Silva NL   1996   Rats   0.75mg/kg   Female
Jones GH   1994   Mice   0.78mg/kg   Male
Brioni   1994   Rats   0.997mg/kg   Male
Brioni   1994   Mice   0.997mg/kg   Male
Ramanathan M   1998   Rats   1mg/kg   Female and Male
Micale   2009   Mice   1mg/kg   Male
Martinez AL   2006   Mice   1mg/kg   Male
Leggio   2011   Mice   1mg/kg   Male
Leggio   2011   Mice   1mg/kg   Male
Sugiyama A   2012   Rats   1mg/kg   Male
Saitoh A   2013   Rats   1mg/kg   Male
Kumar D   2014   Rats   1mg/kg   Female and Male
Gonzalez−Trujano ME   2012   Mice   1mg/kg   Male
Karim N   2011   Mice   1mg/kg   Male
Carro−Juarez M   2012   Rats   1mg/kg   Male
Silva   2007   Mice   1mg/kg   Male
Melo FH   2010   Mice   1mg/kg   Male
Yamada K   2000   Mice   1mg/kg   Not specified
Ven..ncio ET   2011   Rats   1mg/kg   Male
Yad av  AV   2008   Mice   1mg/kg   Male
Kumar D   2014   Rats   1mg/kg   Female and Male
Ochoa−Sanchez R   2012   Rats   1mg/kg   Male
Thippeswamy BS   2011   Mice   1mg/kg   Male
Lolli LF   2007   Mice   1mg/kg   Male
Lolli LF   2007   Mice   1mg/kg   Male
Peng WH   2004   Mice   1mg/kg   Male
Fajemiroye JO   2014   Mice   1mg/kg   Male
Girish C   2013   Mice   1mg/kg   Male
Girish C   2013   Mice   1mg/kg   Male
N
c
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[ −1.15;  0.254]
[ −1.07;  0.609]
[ −0.57;  1.572]
[ −0.54;  1.600]
[  0.32;  2.818]
[  1.22;  4.440]
[ −1.41;  0.581]
[ −3.32; −0.626]
[ −3.31; −0.399]
[ −2.19;  0.090]
[ −1.49;  0.233]




[ −0.96;  0.718]
[ −1.02;  1.243]
[ −1.21;  0.199]
[ −2.21;  0.014]









[ −2.26;  0.041]
[ −1.96; −0.223]
[ −1.70; −0.371]
[ −2.16;  0.280]
[ −1.73; −0.005]
[ −1.97;  0.415]
[ −1.45; −0.094]
[ −1.43; −0.015]
[ −1.39;  0.398]
[ −1.48;  0.514]
[ −0.98;  0.459]
[ −0.92;  0.432]
[ −1.18;  1.084]
[ −0.81;  0.858]




[ −0.68;  0.918]
[ −0.65;  1.022]
[ −0.17;  1.481]
[ −3.40; −0.822]
[ −1.45;  0.546]













































































































Fig. 3. Meta-analysis of diazepam on rodent anxiety related behavior. Meta-analysis of rodent diazepam effect sizes, shown as a forest plot of standardized effect sizes
(Hedges’g).  The meta-analysis is sub-grouped by animal species. Error bars indicate the 95% conﬁdence intervals of standardized mean difference. The weighted average
mean  effect size of subgroups and all studies is represented by the central vertices of a red diamond; the outer vertices indicate the 95% conﬁdence intervals. Control and
treatment samples sizes are given in the columns listed as NC and NT respectively. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to
the  web  version of this article.)
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−10 −5 0 5 10
Standardised 
mean difference SMD 95%−CI Weight
Micale   2008   Mice   1mg/kg   Male
Saiyudthong   2011   Rats   1mg/kg   Male
Consoli D   2007   Mice   1mg/kg   Male
Nagaraja TS   2012   Mice   1mg/kg   Male
Girish C   2013   Mice   1mg/kg   Male
Tai wo AE   2012   Rats   1mg/kg    Female
Micale   2009   Mice   1mg/kg   Male
de Sousa FC   2007   Mice   1mg/kg   Male
Gomes PB   2010   Mice   1mg/kg   Male
Bahi A   2014   Mice   1mg/kg   Male
Harada K   2006   Rats   1mg/kg   Male
Barbosa PR   2008   Rats   1mg/kg   Male
Mansouri MT   2014   Rats   1mg/kg   Male
Blainski A   2010   Mice   1mg/kg   Male
Wang X   2015   Mice   1mg/kg   Male
Mansouri MT   2014   Rats   1mg/kg   Male
de−Paris F   2000   Rats   1mg/kg   Male
Nagaraja TS   2012   Mice   1mg/kg   Male
Rejon−Orantes JC   2013   Mice   1mg/kg   Male
de Sousa FC   2007   Mice   1mg/kg   Male
Kebeb ew Z   2013   Mice   1mg/kg   Male
Ponten   2011   Mice   1mg/kg   Male
de Melo CT   2006   Mice   1mg/kg   Male
Cechin EM   2003   Rats   1mg/kg   Male
Sorra K   2014   Mice   1mg/kg   Male
Tai wo AE   2012   Rats   1mg/kg   Male
Rochford J   1997   Mice   1mg/kg   Male
Sugiyama A   2012   Rats   1mg/kg   Male
Dunn   1998   Rats   1mg/kg   Male
Lepicard EM   2000   Mice   1mg/kg   Male
Kuriba ra   2000   Mice   1mg/kg   Male
Huerta−R eyes M   2013   Mice   1mg/kg    Female and Male
Tai wo AE   2012   Rats   1mg/kg   Male
Kalouda T   2015   Rats   1mg/kg   Male
Tai wo   2012   Rats   1mg/kg   Male
Thongsaard W   1996   Rats   1mg/kg   Male
Yasumatsu H   1994   Rats   1mg/kg   Male
Raquibul Hasan SM   2009   Mice   1mg/kg   Male
Hasen..h rl  RU   1996   Rats   1mg/kg   Male
Bhattacha rya   1991   Mice   1mg/kg   Male
Mechan AO   2002   Rats   1mg/kg   Male
Pell ow S   1985   Rats   1mg/kg   Male
Parent AJ   2012   Rats   1mg/kg   Male
Thongsaard W   1996   Rats   1mg/kg   Male
Mora S   2005   Rats   1mg/kg    Female and Male
Griebel G   1999   Rats   1mg/kg   Male
Cole   1995   Mice   1mg/kg   Male
Lepicard EM   2000   Mice   1mg/kg   Male
Paine  TA   2002   Rats   1mg/kg   Male
Mechan AO   2002   Rats   1mg/kg   Male
Frassetto   2010   Rats   1mg/kg   Male
Hui   2002   Mice   1mg/kg   Male
Sakaue M1   2003   Mice   1mg/kg   Male
Chen   2004   Mice   1mg/kg   Male
Faria   1997   Rats   1mg/kg   Male
Griebel G   1998   Rats   1mg/kg   Male
Tai wo AE   2012   Rats   1mg/kg    Female
Tai wo   2012   Rats   1mg/kg    Female
Griebel G   2002   Rats   1mg/kg   Male
Jaszbe renyi M   2007   Rats   1mg/kg   Male
Griebel G   1999   Rats   1mg/kg   Male
Okuyama S   1999   Rats   1mg/kg   Male
Wanasuntron wong   2012   Mice   1mg/kg   Male
Da Sil va NL   1996   Rats   1mg/kg   Male
Fernandez SP   2008   Mice   1mg/kg   Male
Jaszberenyi   2009   Rats   1mg/kg   Male
Steiner MA   2012   Rats   1mg/kg   Male
Leggio   2011   Mice   1mg/kg   Male
Leggio   2011   Mice   1mg/kg   Male
Da Sil va NL   1996   Rats   1mg/kg    Female
Meyer L   2013   Rats   1.25mg/kg   Male
Dunn RW   1989   Rats   1.25mg/kg   Male
Meyer L   2013   Rats   1.25mg/kg   Male
Klodzinska   2004   Rats   1.25mg/kg   Male
Klodzinska   2004   Rats   1.25mg/kg   Male
Tatarczynska E   2004   Rats   1.25mg/kg   Male
Wes olowska A   2007   Rats   1.25mg/kg   Male
Jastrzebska−Wi..sek M   2014   Rats   1.25mg/kg   Male
Simpson J   2012   Rats   1.25mg/kg   Male
Molina−Hernendez M   2004   Rats   1.3mg/kg   Male
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[ −3.22;  0.205]
[ −2.48; −0.456]
[ −2.60; −0.325]


















[ −1.68;  0.069]
[ −1.42; −0.098]
[ −1.45; −0.069]
[ −1.70;  0.330]
[ −1.59;  0.319]
[ −1.44;  0.278]
[ −1.25;  0.164]
[ −1.22;  0.153]
[ −1.39;  0.393]
[ −1.45;  0.448]
[ −1.24;  0.453]
[ −1.24;  0.528]
[ −1.22;  0.547]
[ −1.17;  0.519]
[ −1.38;  0.734]
[ −1.19;  0.576]
[ −0.97;  0.514]
[ −1.14;  0.715]
[ −1.00;  0.605]
[ −0.95;  0.657]
[ −0.92;  0.829]
[ −0.83;  0.771]
[ −1.05;  1.048]
[ −1.05;  1.048]




[ −1.92;  0.293]
[ −1.91;  0.300]
[ −1.94;  0.360]
[ −1.74;  0.299]
[ −1.65;  0.370]
























































































2Griebel G   1997   Rats   1.5mg/kg   Male   11 15.03 15.549
Fig. 3. ajor rodent ARDEB assays: EPM, OF and LD. This review identiﬁed
72 articles containing relevant data (Assie et al., 1993; Bahi et al.,
014; Barbosa et al., 2008; Baretta et al., 2012; Barnes et al., 1990;5.45 30.03 −1.63 [ −2.61; −0.638]  0.3%
inued)Bellavite et al., 2011; Belzung and Agmo, 1997; Bhatt et al., 2013;
Bhattacharya and Mitra, 1991; Birkett et al., 2011; Blainski et al.,
2010; Borsini et al., 1993; Brioni et al., 1994; Carneiro et al., 2005;
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−10 −5 0 5 10
Standardised 
mean difference SMD 95%−CI Weight
Dalvi A   2001   Mice   1.5mg/kg   Male
Rago L   1988   Mice   1.5mg/kg   Male
Sherif F   1994   Rats   1.5mg/kg   Male
Dalvi A   1999   Mice   1.5mg/kg   Male
Drapier D   2007   Rats   1.5mg/kg   Male
Stankevicius D   2008   Mice   1.5mg/kg   Not specified
LaBuda   2001   Mice   1.5mg/kg   Female and Male
Jones GH   1994   Mice   1.56mg/kg   Male
Brioni   1994   Rats   1.99mg/kg   Male
Gonzalez−Trujano ME   2012   Mice   2mg/kg   Male
Gupta D   2014   Mice   2mg/kg   Male
Gupta D   2015   Mice   2mg/kg   Female and Male
Kurhe YV   2014   Mice   2mg/kg   Male
de Almeida   2012   Mice   2mg/kg   Male
Karim N   2011   Mice   2mg/kg   Male
Carro−Ju..rez M   2012   Rats   2mg/kg   Male
Swami SU   2014   Mice   2mg/kg   Male
Fortes  AC   2013   Mice   2mg/kg   Male
Carneiro LM   2005   Rats   2mg/kg   Female and Male
Bhatt S   2013   Mice   2mg/kg   Male
Carro−Juarez M   2012   Rats   2mg/kg   Male
Han H   2009   Mice   2mg/kg   Male
Lepicard EM   2000   Mice   2mg/kg   Male
Yao Y   2010   Mice   2mg/kg   Male
Rochford J   1997   Mice   2mg/kg   Male
Karim N   2011   Mice   2mg/kg   Male
Pell ow S   1985   Rats   2mg/kg   Male
Fatu ri CB   2010   Rats   2mg/kg   Male
Chen SW   2005   Mice   2mg/kg   Male
Contre ras CM   2011   Rats   2mg/kg    Female
de la  Pena JB   2013   Mice   2mg/kg   Male
Fernandez SP   2008   Mice   2mg/kg   Male
Karim N   2011   Mice   2mg/kg   Male
Schmitt   2002   Rats   2mg/kg   Male
Vol ke V   1998   Rats   2mg/kg   Male
Chen SW   2005   Mice   2mg/kg   Male
Molander AC   2011   Rats   2mg/kg   Male
Schmitt   2001   Rats   2mg/kg   Male
Mi XJ   2005   Mice   2mg/kg   Male
Contre ras CM   2011   Rats   2mg/kg   Male
Santos Rosa D   2012   Rats   2mg/kg   Male
Zhang LM   2014   Mice   2mg/kg   Male
Griebel G   1999   Rats   2mg/kg   Male
Colla AR   2015   Mice   2mg/kg   Male
Molander AC   2011   Rats   2mg/kg   Male
Griebel G   1998   Rats   2mg/kg   Male
Cha HY   2005   Mice   2mg/kg   Male
Cha HY   2005   Mice   2mg/kg   Male
Cha HY   2005   Mice   2mg/kg   Male
Cha HY   2005   Mice   2mg/kg   Male
Fernandez F   2004   Rats   2mg/kg   Male
Cha HY   2005   Mice   2mg/kg   Male
Liu J   2015   Mice   2mg/kg   Male
Engin E   2009   Rats   2mg/kg   Male
Lepicard EM   2000   Mice   2mg/kg   Male
Wanasuntronwong   2012   Mice   2mg/kg   Male
Sakaue M1   2003   Mice   2mg/kg   Male
Fraser LM   2010   Mice   2mg/kg    Female and Male
Liu J   2015   Mice   2mg/kg   Male
Pain L   1999   Rats   2mg/kg   Male
Paine  TA   2002   Rats   2mg/kg   Male
Boerngen−Lacerda   2000   Mice   2mg/kg   Male
Karaka.. A   2011   Rats   2mg/kg   Male
Tatarczynska E   2004   Rats   2.5mg/kg   Male
Wes olowska A   2007   Rats   2.5mg/kg   Male
Klodzinska A   2004   Rats   2.5mg/kg   Male
Klodzinska   2004   Rats   2.5mg/kg   Male
Dunn RW   1989   Rats   2.5mg/kg   Male
de Castro PC   2007   Rats   2.5mg/kg   Male
Jastrzebska−Wiesek M   2014   Rats   2.5mg/kg   Male
Drapier D   2007   Rats   2.5mg/kg   Male
Yasumatsu H   1994   Rats   2.5mg/kg   Male
Flores JA   2006   Rats   2.5mg/kg   Male
Simpson J   2012   Rats   2.5mg/kg   Male
Harro J   1990   Mice   2.5mg/kg   Male
Popik P   2006   Rats   2.5mg/kg   Male
Wada T   1991   Rats   2.5mg/kg   Male
Brioni   1994   Rats   2.99mg/kg   Male
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[ −1.81;  0.045]
[ −1.74;  0.021]
[ −1.32;  0.460]
[ −1.26;  0.511]
[ −3.32; −0.701]













































[ −1.85;  0.015]
[ −1.50; −0.171]
[ −1.80;  0.149]
[ −1.49; −0.091]
[ −1.46;  0.020]
[ −1.43;  0.047]
[ −1.43;  0.557]
[ −1.27;  0.701]
[ −1.18;  0.617]










[ −2.03;  0.211]
[ −2.11;  0.313]
[ −1.70;  0.222]
[ −1.20; −0.043]
[ −0.92;  0.680]






















































































2Stemmelin J   2008   Rats   3mg/kg   Male
Griebel G   2002   Rats   3mg/kg   Male










Fig. 3. arro-Juarez et al., 2012; Cechin et al., 2003; Cha et al., 2005; Chen
t al., 2004, 2005; Choleris et al., 2001; Cole and Rodgers, 1995; Colla
t al., 2015; Consoli et al., 2007; Contreras et al., 2011; Costa et al.,















inued)2001, 1999; de A. Vieira et al., 2013; de Almeida et al., 2012; de
Castro et al., 2007; de Melo et al., 2006; de Sousa et al., 2007; de-
Paris et al., 2000; Drapier et al., 2007; Dunn et al., 1989, 1998; Ene
et al., 2015; Engin et al., 2009; Ennaceur et al., 2010; Fajemiroye
F. Mohammad et al. / Neuroscience and Biobehavioral Reviews 68 (2016) 504–529 511







−10 −5 0 5 10
Standardised 
mean difference SMD 95%−CI Weight
Assay = LD 
Random effects model
Heterogeneity: I−squared=67.8%, tau−squared=0.5613, p<0.0001
Steiner MA   2012   Rats   3mg/kg   Male
Okuyama S   1999   Rats   3mg/kg   Male
Jones GH   1994   Mice   3.13mg/kg   Male
Harada K   2006   Rats   3.2mg/kg   Male
Fraser LM   2010   Mice   4mg/kg   Female and Male
Carro−Juarez M   2012   Rats   4mg/kg   Male
Moreira MR   2014   Rats   5mg/kg   Male
Tatarczynska E   2004   Rats   5mg/kg   Male
Klodzinska A   2004   Rats   5mg/kg   Male
Klodzinska   2004   Rats   5mg/kg   Male
Weso..owska A   2007   Rats   5mg/kg   Male
Larissa FdA   2013   Mice   5mg/kg   Male
Yasumatsu H   1994   Rats   5mg/kg   Male
Jastrzebska−Wiesek M   2014   Rats   5mg/kg   Male
Harro J   1990   Rats   5mg/kg   Male
Wada T   1991   Rats   5mg/kg   Male
Simpson J   2012   Rats   5mg/kg   Male
Popik P   2006   Rats   5mg/kg   Male
Langen B   2005   Rats   6mg/kg   Male
Jones GH   1994   Mice   6.25mg/kg   Male
Tanaka M   2013   Mice   10mg/kg   Male
Hazim AI   2014   Rats   10mg/kg   Male
Hazim AI   2014   Rats   10mg/kg   Male
Okuyama S   1999   Rats   10mg/kg   Male
Griebel G   2002   Rats   10mg/kg   Male
Wada T   1991   Rats   10mg/kg   Male
Wada T   1991   Rats   10mg/kg   Male
Yasumatsu H   1994   Rats   10mg/kg   Male
Steiner MA   2012   Rats   10mg/kg   Male
Harada K   2006   Rats   10mg/kg   Male
Popik P   2006   Rats   10mg/kg   Male
Jones GH   1994   Mice   12.5mg/kg   Male
Rex   2002   Rats   15mg/kg   Male
Popik P   2006   Rats   20mg/kg   Male
Wikinski SI   2001   Rats   0.03mg/kg   Male
Costall   1990   Mice   0.063mg/kg   Male
Barnes NM   1990   Mice   0.063mg/kg   Male
Wikinski SI   2001   Rats   0.1mg/kg   Male
Costall   1990   Mice   0.125mg/kg   Male
Barnes NM   1990   Mice   0.125mg/kg   Male
Costall   1990   Mice   0.25mg/kg   Male
Barnes NM   1990   Mice   0.25mg/kg   Male
Wikinski SI   2001   Rats   0.3mg/kg   Male
Birkett   2011   Mice   0.3mg/kg   Male
Harada K   2006   Mice   0.32mg/kg   Male
Mahendra P   2011   Mice   0.5mg/kg   Male
Costall   1990   Mice   0.5mg/kg   Male
Barnes NM   1990   Mice   0.5mg/kg   Male
Zheng   2009   Mice   0.5mg/kg   Female and Male
Sugiyama A   2012   Rats   1mg/kg   Male
Yad av  AV   2008   Mice   1mg/kg   Male
Pires LF   2013   Mice   1mg/kg   Male
Saitoh A   2013   Rats   1mg/kg   Male
Fajemir oye JO   2014   Mice   1mg/kg   Male
Ishaq H   2014   Rats   1mg/kg   Male
Galeotti N   2013   Mice   1mg/kg   Male
Thippeswamy BS   2011   Mice   1mg/kg   Male
Fernandez SP   2008   Mice   1mg/kg   Male
Costall   1990   Mice   1mg/kg   Male
Barnes NM   1990   Mice   1mg/kg   Male
Ven..ncio ET   2011   Rats   1mg/kg   Male
Belzung C   1997   Mice   1mg/kg   Male
Okuyama S   1999   Mice   1mg/kg   Male
Wikinski SI   2001   Rats   1mg/kg   Male
Wanasuntronwong   2012   Mice   1mg/kg   Male
Harada K   2006   Mice   1mg/kg   Male
Belzung C   1997   Mice   1mg/kg   Male
Costa   2011   Mice   1mg/kg   Male
Bellavite P   2011   Mice   1mg/kg   Male
Birkett   2011   Mice   1mg/kg   Male
Kurhe YV   2014   Mice   2mg/kg   Male
Gupta D   2014   Mice   2mg/kg   Male
Swami SU   2014   Mice   2mg/kg   Male
Bhatt S   2013   Mice   2mg/kg   Male
Gupta D   2015   Mice   2mg/kg    Female and Male
Karim N   2011   Mice   2mg/kg   Male
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[ −2.11;  0.315]
[ −1.37; −0.190]
[ −1.17;  0.449]









[ −1.63;  0.044]
[ −1.50; −0.052]
[ −1.25; −0.089]
[ −1.81;  0.888]
[ −1.72;  0.121]
[ −1.54; −0.345]
[ −1.39;  0.399]
[ −1.41;  1.080]
[ −0.93;  0.820]
[ −2.51; −0.482]




[ −1.45;  0.344]
[ −0.90;  0.726]


















[ −1.53;  0.132]
[ −1.48;  0.317]
[ −1.48;  0.406]
[ −1.17;  0.106]
[ −1.26;  0.367]
[ −1.46;  0.663]
[ −0.68; −0.012]


























































































2Karim N   2011   Mice   2mg/kg   Male    8 25.04 10.990
Fig. 3. t al., 2014; Faria et al., 1997; Faturi et al., 2010; Fernandez et al.,
004, 2008; Flores et al., 2006; Fortes et al., 2013; Fraser et al.,
010; Frassetto et al., 2010; Galeotti et al., 2013; Girish et al., 2013;0.18  5.08 −2.78 [ −4.25; −1.304]  0.2%
inued)Gomes et al., 2010; Gonzalez-Trujano et al., 2006, 2015; González-
Pardo et al., 2006; Griebel et al., 1998, 1997, 1999a,b, 2002; Guilloux
et al., 2013; Gupta et al., 2014, 2015; Han et al., 2009; Harada
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−10 −5 0 5 10
Standardised 
mean difference SMD 95%−CI Weight
Random effects model
Assay = OF 
Random effects model
Random effects model
Heterogeneity: I−squared=67.9%, tau−squared=0.5407, p<0.0001
Heterogeneity: I−squared=65.2%, tau−squared=0.357, p<0.0001
Mi XJ   2005   Mice   2mg/kg   Male
Wanasuntronwong   2012   Mice   2mg/kg   Male
Liu J   2015   Mice   2mg/kg   Male
Chen SW   2005   Mice   2mg/kg   Male
Radulovi.. NS   2013   Mice   2mg/kg   Male
Fernandez F   2004   Rats   2mg/kg   Male
Liu J   2015   Mice   2mg/kg   Male
Colla AR   2015   Mice   2mg/kg   Male
Fernandez SP   2008   Mice   2mg/kg   Male
Santos Rosa D   2012   Rats   2mg/kg   Male
Flores JA   2006   Rats   2.5mg/kg   Male
Griebel G   2002   Rats   2.5mg/kg   Male
Okuyama S   1999   Mice   3mg/kg   Male
Griebel G   2002   Rats   3mg/kg   Male
Birkett   2011   Mice   3mg/kg   Male
Harada K   2006   Mice   3.2mg/kg   Male
Onusic   2002   Rats   4mg/kg   Male
Morei ra MR   2014   Rats   5mg/kg   Male
Borsini F   1993   Mice   5mg/kg   Male
Okuyama S   1999   Mice   10mg/kg   Male
Tanaka M   2013   Mice   10mg/kg   Male
Costall   1990   Mice   10mg/kg   Male
Harada K   2006   Mice   10mg/kg   Male
Stefanski R   1992   Rats   0.05mg/kg   Male
Plaznik A   1994   Rats   0.05mg/kg   Male
Jessa M   1996   Rats   0.05mg/kg   Male
Jessa M   1996   Rats   0.05mg/kg   Male
Stefa..ski R   1992   Rats   0.1mg/kg   Male
Plaznik A   1994   Rats   0.1mg/kg   Male
Ene HM   2015   Mice   0.25mg/kg   Male
Mesfin M   2014   Mice   0.5mg/kg   Male
Ennaceur A   2010   Mice   0.5mg/kg   Male
Stefa..ski R   1992   Rats   0.5mg/kg   Male
Ene HM   2015   Mice   0.5mg/kg   Male
Bahi A   2014   Mice   1mg/kg   Male
Saitoh A   2013   Rats   1mg/kg   Male
Sugiyama A   2012   Rats   1mg/kg   Male
Kebebew Z   2013   Mice   1mg/kg   Male
Ennaceur A   2010   Mice   1mg/kg   Male
Wanasuntron wong   2012   Mice   1mg/kg   Male
Thompson T   2015   Mice   1mg/kg   Male
Birkett   2011   Mice   1mg/kg   Male
Bellavite P   2011   Mice   1mg/kg   Male
Bellavite P   2011   Mice   1mg/kg   Male
Ochoa−Sanchez R   2012   Rats   1mg/kg   Male
Guilloux JP   2013   Mice   1.5mg/kg   Male
Choleris   2001   Mice   1.5mg/kg   Male
Kurhe YV   2014   Mice   2mg/kg   Male
Kong WX   2006   Rats   2mg/kg   Male
Colla AR   2015   Mice   2mg/kg   Male
Karaka.. A   2011   Rats   2mg/kg   Male
Liu J   2015   Mice   2mg/kg   Male
Liu J   2015   Mice   2mg/kg   Male
Fernandez F   2004   Rats   2mg/kg   Male
Wanasuntron wong   2012   Mice   2mg/kg   Male
Thompson T   2015   Mice   2mg/kg   Male
Ennaceur A   2010   Mice   3mg/kg   Male
Birkett   2011   Mice   3mg/kg   Male
Gonz..lez− Pardo   2006   Rats   5mg/kg   Male
Langen B   2005   Rats   6mg/kg   Male
Hazim AI   2014   Rats   10mg/kg   Male
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[ −2.24;  0.222]
[ −1.98;  0.114]
[ −1.67; −0.158]
[ −1.74;  0.304]
[ −1.42;  0.223]





[ −1.03;  0.465]
[ −1.35; −0.040]





[ −2.97;  0.005]
[ −1.63; −0.298]
[ −2.10;  0.023]
[ −1.78;  0.272]
[ −1.00;  0.960]
[ −0.46;  1.547]
[ −2.18; −0.036]
[ −0.60;  1.384]
[ −0.70;  1.507]
[ −1.88;  0.485]
[ −1.19;  0.668]
[ −1.02;  0.936]





[ −1.50;  0.443]
[ −1.47;  0.414]
[ −1.13;  0.834]
[ −0.74;  0.766]
[ −0.31;  0.362]
[ −0.30;  0.369]
[ −0.78;  0.980]
[ −2.11; −0.271]




[ −2.63;  0.189]
[ −1.74; −0.211]
[ −1.73; −0.208]
[ −1.76;  0.286]
[ −1.44;  0.442]
[  0.93;  3.587]
[ −1.68;  0.295]
[ −0.77;  0.716]
[ −0.74;  1.019]
[ −1.43;  0.217]
[ −3.81; −1.061]












































































eHeterogeneity: I−squared=70.4%, tau−squared=0.5975, p<0.0001
Fig. 3. 
t al., 2006; Hasenohrl et al., 1996; Hazim et al., 2014; Huerta-
eyes et al., 2013; Hui et al., 2002; Ishaq, 2014; Jain et al., 2005;
astrzebska-Wiesek et al., 2014; Jászberényi et al., 2009, 2007;
essa et al., 1996; Jones et al., 1994; Kalouda and Pitsikas, 2015;
arakas et al., 2011; Karim et al., 2011; Kebebew and Shibeshi,
013; Klodzinska et al., 2004a,b; Kong et al., 2006; Kumar and
hat, 2014; Kurhe et al., 2014; Kuribara et al., 2000; de la Pena
t al., 2013; LaBuda and Fuchs, 2001; Langen et al., 2005; Leggio
t al., 2011; Lepicard et al., 2000; Liu et al., 2015a,b; Lolli et al.,inued)
2007; Mahendra and Bisht, 2011; Mansouri et al., 2014; Martinez
et al., 2006; Mechan et al., 2002; Melo et al., 2010; Mesﬁn et al.,
2014; Meyer et al., 2013; Mi  et al., 2005; Micale et al., 2009, 2008;
Molander et al., 2011; Molina-Hernandez et al., 2004; Mora et al.,
2005; Moreira et al., 2014; Nagaraja et al., 2012; Ochoa-Sanchez
et al., 2012; Ognibene et al., 2008; Okuyama et al., 1999; Onusic
et al., 2002; Pain et al., 1999; Paine et al., 2002; Parent et al., 2012;
Pellow et al., 1985; Peng et al., 2004; Pires et al., 2013; Plaznik
































































sF. Mohammad et al. / Neuroscience an
013; Rago et al., 1988; Ramanathan et al., 1998; Raquibul Hasan
t al., 2009; Rejon-Orantes et al., 2013; Rex et al., 2002; Rochford
t al., 1997; Saiyudthong and Marsden, 2011; Sakaue et al., 2003;
antos Rosa et al., 2012; Satyan et al., 1998; Schmitt et al., 2002,
001; Sherif et al., 1994; Silva et al., 2007; Simpson and Kelly, 2012;
orra et al., 2014; Srinivasan et al., 2003; Stankevicius et al., 2008;
tefanski et al., 1992; Steiner et al., 2012; Stemmelin et al., 2008;
ugiyama et al., 2012; Swami et al., 2014; Taiwo et al., 2012; Tanaka
t al., 2013; Tatarczynska et al., 2004; Thippeswamy et al., 2011;
hompson et al., 2015; Thongsaard et al., 1996; Tolardo et al., 2010;
arty et al., 2002; Venancio et al., 2011; Volke et al., 1998; Wada and
ukuda, 1991; Wanasuntronwong et al., 2012; Wang et al., 2015;
esolowska and Nikiforuk, 2007; Wikinski et al., 2001; Wolfman
t al., 1994; Yadav et al., 2008; Yamada et al., 2000; Yao et al.,
010; Yasumatsu et al., 1994; Zanoli et al., 2002; Zhang et al., 2014;
heng et al., 2009). Calculation of an average Hedges’g (Cumming,
012) for the 386 experiments contained therein indicated that
iazepam had a very large effect on ARDEB, with a −1.26 g [95CI
1.36, −1.17] reduction compared with untreated control animals
Fig. 3, Table 2). However, as Egger’s regression indicated the source
iterature was  affected by publication bias, trim-and-ﬁll correction
ndicated a smaller – though still large – effect of −0.85 g [95CI
0.74, −0.96]. The meta-analysis had a moderate level of hetero-
eneity (I2 = 70.4%). Subgroup analysis of assay types suggest that
ssays were not major source of heterogeneity (Fig. 3). Subgroup
nalysis of the assay types showed that EPM and LD yielded very
imilar diazepam effect sizes (g = −1.33 and −1.37 respectively,
ig. 3). However, the diazepam effect size in OF was  found to be sub-
tantially smaller (g = −0.53, Fig. 3). Additional subgroup analyses
f treatment duration variables, dosages and route of treatments
evealed that these factors were also only minor sources of het-
rogeneity (data not shown), indicating that laboratory, dosage,
train and other possible sources of experimental variation likely
lay a role. As diazepam is universally accepted to be an effective
nxiolytic, and it has a robust (bias-corrected) effect in the rodent
RDEB assays, this meta-analytic result veriﬁes the validity of the
efense behavior tests.
.6. 5-HT1A receptor function inﬂuences ARDEB
Following negative publicity regarding the adverse effects of
enzodiazepines (Tone, 2009), pharmaceutical companies focused
n the serotonergic system (Griebel and Holmes, 2013). Of the four-
een mammalian serotonergic receptors, much investigation has
entered on the serotonin receptor 5-HT1A and its proposed inﬂu-
nce on anxiety disorders and depression (Samuels et al., 2014).
ore than 1200 articles describe experiments connecting 5-HT1A
gonism with rodent anxiety (Griebel and Holmes, 2013). However,
 substantial proportion of those articles reported that 5-HT1A ago-
ists or knockout of the Htr1a gene either produced no effect on
nxiety or an effect that was opposite to the receptor’s proposed
ode of action (Griebel and Holmes, 2013). We  systematically
eviewed the literature on gene manipulations of Htr1a and identi-
ed 11 knockout articles (Ferrés-Coy et al., 2013; Freeman-Daniels
t al., 2011; Gleason et al., 2010; Groenink et al., 2003; Gross et al.,
002; Jain et al., 2012; Klemenhagen et al., 2006; Parks et al., 1998;
iszczek et al., 2013; Ramboz et al., 1998; Vinkers et al., 2010).
eta-analysis of the knockout data revealed that removal of Htr1a
roduced a moderate increase (Hedges’ g = 0.73 [95CI 0.50, 0.96],
 = 3.5 × 10−10) in ARDEB phenotypes (Fig. 4A). The three studies
f Htr1a overexpression found by the review (Audero et al., 2013;
ert et al., 2006; Kusserow et al., 2004) indicated that this inter-
ention moderately decreased ARDEB (g = −0.6 [95CI −1.3, 0.13],
 = 0.11; Fig. 4B). The cumulative sample size of Htr1a overexpres-
ion is quite substantial (N = 100, 98), though the moderate effect
ize observed was not statistically signiﬁcant and had high hetero-ehavioral Reviews 68 (2016) 504–529 513
geneity (I2 = 80%). These results conﬁrm that Htr1a function has a
moderate effect on rodent anxiety.
3.7. Anxiotropic effects of the serotonin transporter
The serotonin transporter (SERT) is the target for the selective
serotonin reuptake inhibitors (SSRIs), a class of drugs used to treat
depression and anxiety (Baldwin et al., 2014). Meta-analysis of thir-
teen knockout studies (Carroll et al., 2007; Holmes et al., 2003a,b;
Kalueff et al., 2007a,b; Li et al., 2004; Line et al., 2011; Lira et al.,
2003; Moya et al., 2011; Olivier et al., 2008; Pang et al., 2011;
Schipper et al., 2011; Zhao et al., 2006) revealed a large anxiogenic
effect (g = 0.88 [95CI 1.26, 0.23], P = 5.2 × 10−14; Fig. 5A) produced
by knocking out the SERT gene, Htt. However, a funnel plot and
Egger’s regression revealed a pronounced bias in reported effect
sizes (Egger’s test P = 6.7 × 10−6, Table 2). Trim-and-ﬁll adjustment
added ten imputed data points to the left segment of the funnel
plot, lowering the effect size to g = 0.57 [95CI 0.29, 0.86], a moderate
effect. Only two articles studying the effect of Htt overexpression on
ARDEB were found (Jennings et al., 2006; Line et al., 2011). Meta-
analysis revealed a large anxiolytic effect (g = −0.94 [95CI −1.69,
−0.20], P = 0.013; Fig. 5B) in EPM and OF assays (no LD articles were
found). The transporter gene knockout and overexpression effects
clearly connect Htt function to rodent anxiety. However, the direc-
tion of effects is the opposite of what would be expected from the
clinical application of SERT inhibitors, given that SSRI reduction of
SERT function is believed to have a therapeutic, anxiety-reducing
effect.
3.8. The effect of acute pain on rodent anxiety
Environmental stressors have physiological effects on animals
that promote the anxiety-like state (van Praag, 2003). To survey a
range of stress modalities we  selected acute pain, bodily restraint
and social isolation for review; all three have been found to pro-
mote anxiety in humans (Sherif and Oreland, 1995). The systematic
review identiﬁed seven papers measuring the effect of acute pain
on ARDEB (Benbouzid et al., 2008; Leite-Almeida et al., 2012; Liu
et al., 2015a,b; Matsuzawa-Yanagida et al., 2008; Parent et al., 2012;
Schellinck et al., 2003; Shang et al., 2014). Meta-analysis of the
21 experiments therein indicated a moderate anxiogenic effect
(g = 0.56 [95CI 0.19, 0.93], P = 2.9 × 10−3; Fig. 6A).
3.9. The effect of bodily restraint on rodent anxiety
Review of 16 studies of rodent bodily restraint (Anand et al.,
2012; Busnardo et al., 2013; Carvajal et al., 2004; Chesworth et al.,
2012; Estanislau and Morato, 2005; Granjeiro et al., 2011; Harris
et al., 2001; Joshi et al., 2014; Liu et al., 2011; Locchi et al., 2008;
Lunga and Herbert, 2004; Nosek et al., 2008; Ouagazzal et al., 2003;
Reis et al., 2011; Rylkova et al., 2009; Walf and Frye, 2012) con-
taining 21 experiments indicated that it had an overall moderate
anxiogenic effect in EPM and OF assays (g = 0.70 [95% CI 0.82 − 1.32],
P = 0.027; Fig. 6B). The restraint meta-analysis had a high level of
heterogeneity, I2 = 89%; a subgroup analysis by assay type revealed
that the different assays were not the source of this variability (data
not shown).
3.10. Social isolation has a small effect on rodent defense
behaviors
Systematic review identiﬁed 50 articles on social isolation
and ARDEB (Abramov et al., 2004; Blakley and Pohorecky, 2006;
Blednov et al., 2001; Bledsoe et al., 2011; Brenes et al., 2009; Carrier
and Kabbaj, 2012; Chappell et al., 2013; Cheeta et al., 2001; Conrad
et al., 2011; Cuenya et al., 2012; Da Silva et al., 1996; Das et al., 2014;
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Table  2
Results of Egger’s linear regression test for funnel plot asymmetry across six meta-analyses. Where at least twenty experiments were available for meta-analysis, Egger’s
linear  regression test for funnel plot asymmetry was  performed. For each meta-analysis, the number of included studies, the vertical intercept of the linear regression, the
corresponding 95% conﬁdence interval for the intercept, and the P-values of Egger’s test are listed.
Experiments No. of
Studies







g  [95% CI]
p-value Adjusted
Hedges’ g
Diazepam 386 172 −1.3 [−1.4; −1.2] 1.36E-144 0.704 [67.2; 73.3] 2.35E-56 102 −0.85 [−0.96; −0.74] 4.72E-56
Isolation 83 50 0.33 [0.21; 0.44] 3.37E-08 0.269 [3.5; 44.6] 0.0146 12 0.21 [0.069; 0.34] 0.00316
HTT  KO 29 13 0.88 [0.65; 1.1] 5.18E-14 0.503 [23.7; 67.6] 6.72E-06 10 0.57 [0.29; 0.86] 9.71E-05
Restraint 21 16 0.67 [0.0062; 1.3] 0.0479 0.834 [75.8; 88.7] 0.0305 NA NA NA
Pain  21 7 0.56 [0.19; 0.92] 0.00283 0.651 [44.6; 78] 0.763 NA NA NA
5HT1A KO 20 11 0.73 [0.5; 0.96] 3.15E-10 0.28 [0; 58.2] 0.545 NA NA NA












































uCrhr1  KO 8 6 −1 [−1.3; −0.7] 6.64E-11 0.131 [0
Htt  OE 4 2 −0.94 [−1.7; −0.2] 0.0127 0.511 [0
Crh  KO 2 2 0.3 [−0.32; 0.92] 0.34 0 [NA; N
jordjevic et al., 2012; Doremus-Fitzwater et al., 2009; Estelles
t al., 2007; Fone et al., 1996; Haller and Halász, 1999; Haller et al.,
000; Hermes et al., 2011; Hirani et al., 2005; Imanaka et al., 2008,
006; Knuth and Etgen, 2007; Koike et al., 2009; Kokare et al., 2010;
apiz et al., 2001; Leussis and Andersen, 2008; Linge et al., 2013;
iu et al., 2013; Lukkes et al., 2009; Majercsik et al., 2003; McCool
nd Chappell, 2009; Moragrega et al., 2003; Pisu et al., 2013, 2011;
ritchard et al., 2008; Quintino-dos-Santos et al., 2014; Reis et al.,
012; Rodgers and Cole, 1993; Ryu et al., 2009; Santos dos et al.,
010; Serra et al., 2000; Thorsell et al., 2006; Voikar et al., 2005;
ei  et al., 2007; Workman et al., 2011; Wright and Ingenito, 2001;
ildirim et al., 2012; Yorgason et al., 2013; Zhang et al., 2012). Meta-
nalysis revealed a small anxiogenic effect (g = 0.33 [95CI 0.21,
.44], P = 3.4 × 10−8; Fig. 6C), but this included likely publication
ias; the trim-and-ﬁll method corrected the anxiogenic effect to
nly 0.21 g [95CI 0.07, 0.34], P = 3.1 × 10−3) a very small anxiotropic
ffect (Fig. 2B). It appears that, unlike the physical stressors, social
solation has only a modest inﬂuence on the ARDEB assays.
.11. Crh gene knockout has a modest effect on rodent ARDEB
Several neuropeptide-related genes involved in stress signaling
ave been linked to anxiety, notably the peptide, corticotropin-
eleasing hormone (CRH; also known as corticotropin-releasing
actor) (Kormos and Gaszner, 2013) and its receptor, CRHR1. Two
tudies that examined the effects of Crh knockouts on ARDEB were
ound (Weninger et al., 1999), which revealed only a small effect
g = 0.30 [95CI −0.32, 0.92], P = 0.34; Fig. 7A). This supports the idea
hat CRH has only a modest effect on the ARDEB. The meta-analytic
esult may  suffer from insufﬁcient precision as the cumulative sam-
le size was small (N = 20, 21). As publication bias appears to affect
he literature, this small effect could be an overestimate.
.12. Crhr1 gene knockout has a large effect on rodent anxiety
CRH exerts its biological action via two receptors known as
RHR1 and CRHR2. The two receptors are pharmacologically dis-
inct and only the former has been widely studied in the context
f anxiety (Owens and Nemeroff, 1991; Paez-Pereda et al., 2011).
eta-analysis (Gammie and Stevenson, 2006; Liebsch et al., 1999,
995; Müller et al., 2003; Smith et al., 1998; Trimble et al., 2007)
ound that, in contrast to the Crh knockout, deletion of Crhr1 had
 large anxiolytic effect on ARDEB (g = −1.0 [95CI −1.30, −0.70],
 = 6.64 × 10−11; Fig. 7B). The discordance between Crh and Crhr1
nockout effects has previously been attributed to the action
f other peptide ligand(s) of Crhr1, either urocortin or another,
nidentiﬁed ligand (Dunn and Swiergiel, 1999).] NA NA NA NA
] NA NA NA NA
NA NA NA NA
3.13. Species and sex differences in ARDEB
Rats and mice have differences in their defensive behavior when
exposed to predators or predator cues (Blanchard et al., 2001). We
used the synthetic data to examine species differences in base-
line ARDEB prior to anxiotropic manipulation. The LD box showed
the most substantial difference between species −6.88% [−13.3;
−0.46], p = 0.04, but in general, inter-species differences in naive
ARDEB were minor when compared to the overall variance (Fig. 8A).
Where rat data were available, inter-species differences
between the effects of anxiety-related interventions were inves-
tigated. There were only minor inter-species differences in the
meta-analytic effect sizes of the interventions (Fig. 8B). A strik-
ing exception to this trend was  a large rat-mouse difference in the
response to restraint: this treatment appeared strongly anxiogenic
for rats, but modestly anxiolytic for mice.
We investigated sex differences in ARDEB, but found that the
anxiety studies contained ∼18 × fewer experiments on female
rodents than males, rendering any meta-analytic estimates of
female ARDEB imprecise.
3.14. Validity of the ARDEB assays
Of the interventions analyzed above, only diazepam has exten-
sive clinical evidence supporting its ability to alter human anxiety.
The large anxiolytic diazepam effect size observed with the ARDEB
assays veriﬁes their validity (Fig. 9A). The stressors – isolation, acute
pain and restraint – would all be expected to produce increases
in human anxiety, and all show anxiogenic effects in the ARDEB,
thus also verifying the validity of these assays (Fig. 9A), with the
exception of the surprisingly small social isolation effect (0.21 g).
Establishing the validity of animal models relies partly on showing
concordance between models (Campbell and Fiske, 1959; van der
Staay, 2006). To explore the concordance between the three assays,
we conducted regression analyses on all possible two-way compar-
isons of ARDEB (Fig. 9B–D). The LD-EPM and OF-LD comparisons
of ARDEB changes both showed 60% concordance, supporting the
idea that the three assays were measuring similar aspects. How-
ever, surprisingly, the OF-EPM comparison revealed that the two
methods were discordant (R2adj = −0.01, Fig. 9D).
4. Discussion
4.1. Summary of evidenceInspection of the forest plots reveals that all of the primary pub-
lication sets include experimental effect sizes that are discordant,
either in direction (anxiolytic versus anxiogenic) and/or magni-
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Fig. 4. Meta-analyses of serotonin receptor 1A interventions on rodent anxiety-related behaviors. Meta-analysis of effect sizes of serotonin-targeted interventions is shown









dy  the central vertices of a red diamond; the outer vertices indicate the 95% conﬁd
tudies  are given; elevated plus maze (EPM), open ﬁeld (OF) and light-dark box (LD).
For  interpretation of the references to color in this ﬁgure legend, the reader is refe
ude. The generality of discordance in the literature emphasizes
he utility of meta-analysis to behavioral neuroscience to give a
uantitative overview and to synthesize the best evidence avail-
ble. Of ten analyses of putative anxiotropic interventions, eight
ielded at least moderate meta-analytic effect sizes and two  pro-
uced small effect sizes (Fig. 9). The synthetic data strongly conﬁrmintervals. Control and treatment samples sizes (NC, NT) and the assay types of the
s of: (A) Serotonin receptor gene Htr1a knockout models. (B) Htr1a overexpression.
 the web version of this article.)
that diazepam, the serotonergic system, environmental stressors,
and Crhr1 inﬂuence an anxiety-like process in the mouse brain.
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Htt Knockout
Random ef fects model
Heterogeneity: I^2=50.3%,  Tau^2=0.2011, p=0.0012
Assay = EPM
Assay = LD 
Assay = OF 
Random ef fects model
Random ef fects model
Random ef fects model
Heterogeneity: I^2=45.3%,  Tau^2=0.1572, p=0.0384
Heterogeneity: I^2=64.4%,  Tau^2=0.5054, p=0.0154
Heterogeneity: I^2=52.3%,  Tau^2=0.1309, p=0.0263
Holmes, 2003   Mice   Female
Holmes, 2003   Mice   Female
Li, 2004   Mice   Female
Carroll, 2007   Mice   Female and Male
Line, 2011   Mice   Female and Male
Holmes, 2003   Mice   Male
Holmes, 2003   Mice   Male
Holmes, 2003   Mice   Male
Kalueff, 2007   Mice   Male
Kalueff, 2007   Mice   Male
Lira, 2003   Mice   Male
Schipper, 2011   Rats   Female
Olivier, 2008   Rats   Male
Holmes, 2003   Mice   Female
Holmes, 2003   Mice   Female
Carroll, 2007   Mice   Female and Male
Holmes, 2003   Mice   Male
Holmes, 2003   Mice   Male
Holmes, 2003   Mice   Male
Kalueff, 2007   Mice   Female
Carroll, 2007   Mice    Female and Male
Zhao, 2006   Mice   Female and Male
Zhao, 2006   Mice   Female and Male
Holmes, 2003   Mice   Male
Kalueff, 2007   Mice   Male
Kalueff, 2007   Mice   Male
Moya, 2011   Mice   Male
Pang, 2011   Mice   Male
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Random ef fects model
Heterogeneity: I^2=51.1%,  Tau^2=0.2678, p=0.1053
Jenning s, 2006   Mouse   Male   EPM
Jenning s, 2006   Mouse   Male   EPM
Line, 2011   Mouse   Male and  Female   EPM
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[ 2.13;  0.005]
[ 2.85; 0.484]
[ 2.44; 0.205]







Fig. 5. Meta-analyses of serotonin transporter interventions on rodent anxiety-related behaviors. Meta-analysis of effect sizes of serotonin-targeted interventions is shown
as  a forest plot of standardized effect sizes (Hedges’g). Error bars indicate the 95% conﬁdence intervals of g. The weighted average mean effect size of all studies is represented
b ence 
s ). Effec










fy  the central vertices of a red diamond; the outer vertices indicate the 95% conﬁd
tudies  are given; elevated plus maze (EPM), open ﬁeld (OF) and light-dark box (LD
odels. (For interpretation of the references to color in this ﬁgure legend, the reade
.2. Limitations
This study is limited by its exclusive use of English-language
ublished data. Some studies had to be excluded from the
eta-analysis during the full text scan because they did not
eport measures of variance. Only studies that reported time or
ercent time spent in exposed arena could be selected for meta-
nalysis. We found no knowledge gaps per se, as all ten proposed
nxiety-related factors had at least two studies. Nevertheless, Htt
verexpression, Crh knockouts and the non-anxiety genes had lim-
ted cumulative sample sizes (Ncumulative < 64, 64). Of the six factors
or which publication bias was examined, three were affected. Theintervals. Control and treatment samples sizes (NC, NT) and the assay types of the
ts of: (A) Serotonin transporter gene (Htt) knockout models (B) Htt overexpression
ferred to the web version of this article.)
presence of publication bias in the larger data sets suggests that
inclusion of further data to the smaller meta-analyses would be
expected, on average, to lower these effect sizes as well. Hetero-
geneity was at least moderate (I2 > 50%) in ﬁve of the meta-analyses,
indicating that the random effects model is insufﬁcient to explain
the variance in these data sets. Thus, laboratory, strain, assay
type and other protocol variations played variable roles across
factors. Heterogeneity could in theory be reduced by increased
standardization (Crabbe et al., 1999). Multilevel regression models
of these data may  be able to account for the unexplained variance
(Yildizoglu et al., 2015).




Random ef fects model
Heterogeneity: I^2=13.1%,  Tau^2=0, p=0.3278
Gammie, 2006   Mouse   Male   EPM
Mulle r, 2003   Mouse   Male   EPM
Smith, 1998   Mouse   Male   EPM
Trimble, 2007   Mouse   Mix  EPM
Liebsch, 1995   Rats   Male   EPM
Liebsch, 1999   Rats   Male   EPM
Muller, 2003   Mouse   Male   LD
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Heterogeneity: I^2=0%,  Tau^2=0, p=0.9292
Dunn, 1999   Mouse   Male   EPM
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Fig. 6. Meta-analyses of the effects of stress signaling genes on anxiety-related behaviors. Meta-analysis of effect sizes of stress signaling genes, shown as a forest plot of
standardized effect sizes (Hedges’ g). Error bars indicate the 95% conﬁdence intervals of g. The weighted average mean effect size of all studies is represented by the central
v ontro
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levated plus maze (EPM), open ﬁeld (OF) and light-dark box (LD). Effects of: (A)
eferences to color in this ﬁgure legend, the reader is referred to the web  version of
.3. Assay validity
The validity of each ARDEB assay was originally tested with a
anel of anxiotropic agents (Crawley and Goodwin, 1980; Pellow
t al., 1985; Simon et al., 1994). In the decades since the variability of
ssay results and the disappointing clinical outcome of compounds
dentiﬁed with these preclinical assays raise new questions about
heir validity (Griebel and Holmes, 2013). The diazepam, restraint
nd acute pain synthetic data shown here support the ARDEB
ssays’ validity, though two other results raise doubts: (1) the social
solation effect on ARDEB is weaker than expected (Fig. 9A); (2) the
ailure of EPM and OF to reproduce each other’s outcomes (Fig. 9D).
he EPM-OF meta-regression discordance is an exploratory obser-
ation that could be veriﬁed with a formal method comparison with
nimals run through all three assays (Bland and Altman, 1999).
How might the validity of the ARDEB assays be tested fur-
her? First, meta-analyses of additional known anxiotropic agents
ill help assess the assays’ strengths and weaknesses. Second,
ssay validity assessment would be helped by researchers making
heir video or tracking data available (ideally with experimental
etadata in a standard ﬁle format), similar to data sharing efforts
urrently underway in neurophysiology. Anxiety assay validity may
lso be tested with new instrumentation that allows the esti-
ation of animal pose (Nanjappa et al., 2015; Wiltschko et al.,
015) and that will make complex, ethological relevant anxiety
ssays (Blanchard et al., 2001) increasingly accessible for routine
nalysis (Schaefer and Claridge-Chang, 2012). Looking backward
meta-analysis and data sharing) and forward (more reﬁned anxi-
ty assays) are both valuable to rodent anxiety research. It has been
uggested that research consortia should form to overcome the cost
estrictions of large rodent sample sizes (Button et al., 2013); per-l and treatment samples sizes (NC, NT) and the assay types of the studies are given;
ene knockout models. (B) Crhr1 gene knockout models. (For interpretation of the
rticle.)
haps a consortium could form around the problem of anxiety assay
validation.
4.4. Disconnect between Htr1a & Crhr1 preclinical results and
clinical efforts
Meta-analysis of Htr1a overexpression revealed it has a mod-
erate anxiotropic effect (−0.6 g), smaller than the bias-corrected
diazepam effect (−0.85 g), suggesting that compounds aiming
to increase 5-HT1A function may  be a poor strategy to reduce
anxiety. This view is supported by clinical meta-analyses that
have concluded that drugs targeting 5-HT1A – the azapirones –
appear inferior to benzodiazepines for generalized anxiety disorder
(Chessick et al., 2006) and that there is insufﬁcient evidence to sup-
port azapirone use in panic disorder (Imai et al., 2014). It appears
that clinical adoption of the azapirones was/is not informed by
the preclinical genetic evidence base. A second type of preclinical-
clinical disconnect is observed with the Crhr1 knockouts. The
synthetic preclinical data indicate that Crhr1 knockout produces
a very large reduction of rodent anxiety (g = −1.0 [95Ci −0.7, −1.3],
I2 = 13%, Ncumulative = 105, 99). However, at least one clinical trial of a
CRHR1 antagonist for generalized anxiety disorder showed no ben-
eﬁt over placebo (Coric et al., 2010). The discrepancy between the
efﬁcacy of Crhr1 knockouts and inefﬁcacy of CRHR1 antagonists in
patients remains unexplained.
4.5. A paradox in Htt-SSRI anxiety effects
Drugs that inhibit SERT, the SSRIs, are recommended as the ﬁrst
line of pharmacological treatment for anxiety (Baldwin et al., 2014).
Blocking SERT-mediated reuptake of serotonin from the synaptic
cleft is the proposed mechanism of SSRI anxiety reduction, although
rodent studies of chronic SSRI effects on ARDEB have been incon-
518 F. Mohammad et al. / Neuroscience and Biobehavioral Reviews 68 (2016) 504–529
Physical Restraint
Random effects model
Heterogeneity: I^2=83.3%,  Tau^2=2.048, p<0.0001
Assay = EPM
Assay = LD 




Heterogeneity: I^2=83.3%,  Tau^2=1.904, p<0.0001
Heterogeneity: I^2=64.1%,  Tau^2=0.2596, p=0.0949
Heterogeneity: I^2=70.5%,  Tau^2=0.6481, p=0.0171
Harris, 2001   12 mins   Mice   Male
Lunga, 2004   60 mins   Rats   Female
Carvajal, 2004   60 mins   Rats    Female and Male
Rylkova, 2009   15 mins   Rats   Male
Wal f, 2012   20 mins   Rats   Male
Liu, 2013   30 mins   Rats   Male
Locchi, 2007   45 mins   Rats   Male
Anand, 2012   60 mins   Rats   Male
Busnardo, 2013   60 mins   Rats   Male
Estanislau, 2005   60 mins   Rats   Male
Granjeiro, 2011   60 mins   Rats   Male
Joshi JC, 2014   60 mins   Rats   Male
Nosek, 2008   60 mins   Rats   Male
Nosek, 2008   60 mins   Rats   Male
Reis, 2011   60 mins   Rats   Male
Ouagazzal, 2003   5 mins   Mice   Female
Harris, 2001   12 mins   Mice   Male
Chesworth, 2012   15 mins   Mice   Male
Chesworth, 2012   15 mins   Mice   Male
Nosek, 2008   60 mins   Rats   Male
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[ 0.005;  1.32]
[ 0.376;  1.90]
[ 1.239;  0.52]
[ 1.392;  0.47]
[ 2.038; 0.40]
[ 0.749;  3.55]
[ 2.680;  5.72]
[ 1.022;  0.83]
[ 0.112;  1.04]
[ 0.509;  2.63]
[ 1.110;  3.65]
[ 0.949;  4.37]
[ 0.152;  2.30]
[ 0.166;  1.93]
[ 0.155;  2.22]
[ 0.959;  4.39]
[ 0.613;  1.52]
[ 2.821; 0.32]
[ 0.047;  2.66]
[ 0.637;  0.80]
[ 1.596; 0.04]
[ 0.213;  1.51]
[ 0.893;  0.46]
[ 2.696; 0.25]































Heterogeneity: I^2=65.7%,  Tau^2=0.4967, p<0.0001
Assay = EPM
Assay = LD 




Heterogeneity: I^2=64.2%,  Tau^2=0.4142, p=0.0012
Heterogeneity: I^2=92.3%,  Tau^2=3.849, p=0.0003
Heterogeneity: I^2=25.1%,  Tau^2=0.0867, p=0.2372
Shang, 2015   1 d ays   Mice   Male   EPM
Shang, 2015   3 days   Mice   Male   EPM
Shang, 2015   7 d ays   Mice   Male   EPM
Shang, 2015   14 days   Mice   Male   EPM
Liu, 2015   12 days   Mice   Male   EPM
Liu, 2015   12 days   Mice   Male   EPM
Parent, 2012   28 days   Rats   Male   EPM
Leite Almeida, 2009   30 days   Rats   Male   EPM
Benbouzid, 2008   30 d ays   Mice   Male   EPM
Matsuz awa Yanagida, 2008   28 days   Mice   Male   EPM
Leite Almeida, 2009   30 days   Rats   Male   EPM
Schellinck, 2003   0 days   Mice    Female and Male   EPM
Parent, 2012   28 days   Rats   Male   LD
Matsuz awa Yanagida, 2008   28 days   Mice   Male   LD
Shang, 2015   1 d ays   Mice   Male   OF
Shang, 2015   3 d ays   Mice   Male   OF
Shang, 2015   7 days   Mice   Male   OF
Shang, 2015   14 d ays   Mice   Male   OF
Liu, 2015   12 d ays   Mice   Male   OF
Liu, 2015   12 d ays   Mice   Male   OF
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Fig. 7. Meta-analyses of experiments on the stress-anxiety relationship in rodents. Meta-analysis of effect sizes of stress-anxiety interventions, shown as a forest plot of
standardized effect sizes (Hedges’ g). Error bars indicate the 95% conﬁdence intervals of g. The weighted average mean effect size of all studies is represented by the central
vertices  of a red diamond; the outer vertices indicate the 95% conﬁdence intervals. Control and treatment samples sizes (NC, NT) and the assay types of the studies are given;
elevated plus maze (EPM), open ﬁeld (OF) and light-dark box (LD). Effects of: (A) Acute pain. (B) Restraint stress (immobilization). (C) Social isolation. (For interpretation of
the  references to color in this ﬁgure legend, the reader is referred to the web  version of this article.)
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Social Isolation
Random ef fects model
Heterogeneity: I^2=26.9%,  Tau^2=0.1091, p=0.0151
Assay = EPM
Assay = LD 
Assay = OF 
Random ef fects model
Random ef fects model
Random ef fects model
Heterogeneity: I^2=31%,  Tau^2=0.1354, p=0.0103
Heterogeneity: I^2=35.1%,  Tau^2=0.0301, p=0.1735
Heterogeneity: I^2=0%,  Tau^2=0.0157, p=0.4675
Abramov, 2004   21 days   Mice   Female
Blednov  YA, 2001   6 d ays   Mice    Female and Male
Majercsik, 2003   7 d ays   Mice   Male
Majercsik, 2003   7 days   Mice   Male
Majercsik, 2003   7 days   Mice   Male
Majercsik, 2003   7 days   Mice   Male
Rodgers, 1993   7 days   Mice   Male
Estelles J, 2007   14 days   Mice   Male
Rodgers, 1993   14 days   Mice   Male
Abramov, 2004   21 days   Mice   Male
Rodgers, 1993   21 days   Mice   Male
Wei XY, 2007   21 days   Mice   Male
Koike H, 2009   28 days   Mice   Male
Koi ke H, 2009   28 d ays   Mice   Male
Moragrega , 2003   30 days   Mice   Male
Liu X, 2013   42 days   Mice   Male
Workman JL, 2011   42 d ays   Mice   Male
Voikar  V, 2005   49 days   Mice   Male
Imanaka A, 2006   7 days   Rats   Female
Leussis MP, 2008   7 days   Rats   Female
Da Silva NL, 1997   28 days   Rats   Female
Pisu MG, 2013   28 d ays   Rats   Female
Imanaka A, 2009   35 days   Rats   Female
Doremus Fitzwater TL, 2009   49 d ays   Rats   Female
Knuth ED, 2007   7 days   Rats   Female and Male
Reis FM, 2012   0.02 days   Rats   Male
Reis FM, 2012   0.08 d ays   Rats   Male
Reis FM, 2012   1 d ays   Rats   Male
Haller J, 1999   4 days   Rats   Male
Cheeta S, 2001   7 days   Rats   Male
Cheeta S, 2001   7 d ays   Rats   Male
Cheeta S, 2001   7 d ays   Rats   Male
Haller J, 2000   7 days   Rats   Male
Haller J, 2000   7 days   Rats   Male
Leussis MP, 2008   7 days   Rats   Male
Majercsik, 2003   7 d ays   Rats   Male
Majercsik, 2003   7 d ays   Rats   Male
Majercsik, 2003   7 d ays   Rats   Male
Reis FM, 2012   7 days   Rats   Male
Wright, 2001   7 days   Rats   Male
Das SK, 2015   14 days   Rats   Male
dos Santos L, 2010   14 days   Rats   Male
Lapiz MD, 2001   14 d ays   Rats   Male
Lapiz MD, 2001   14 d ays   Rats   Male
Quintino dos Santos J W, 2014   20 d ays   Rats   Male
Bledsoe AC, 2011   21 d ays   Rats   Male
Brenes J C, 2009   28 d ays   Rats   Male
Da Silva NL, 1996   28 days   Rats   Male
Pisu MG, 2011   28 d ays   Rats   Male
Pisu MG, 2014   28 d ays   Rats   Male
Serra M, 2000   28 days   Rats   Male
Cuenya L, 2012   30 days   Rats   Male
Fone K C, 1996   35 d ays   Rats   Male
Fone K C, 1996   35 d ays   Rats   Male
Imanaka A, 2008   35 days   Rats   Male
Chappell AM, 2013   42 days   Rats   Male
Hirani K, 2005   42 d ays   Rats   Male
Kokare DM, 2010   42 d ays   Rats   Male
McCool BA, 2009   42 days   Rats   Male
Pritchard LM, 2008   42 days   Rats   Male
Ryu V, 2009   42 days   Rats   Male
Doremus Fitzwater TL, 2009   49 d ays   Rats   Male
Yildi rim E, 2012   49 days   Rats   Male
Yorgason JT, 2013   49 days   Rats   Male
Zhang Y, 2012   56 days   Rats   Male
Thorsell A, 2006   84 days   Rats   Male
Wei X Y, 2007   21 days   Mice   Male
Voikar  V, 2005   49 days   Mice   Male
Voikar  V, 2005   49 days   Mice   Male
Carrier N, 2012   21 d ays   Rats   Female
Carrier N, 2012   21 d ays   Rats   Male
McCool BA, 2009   42 days   Rats   Male
Linge R, 2013   28 days   Mice   Male
Liu X, 2013   42 days   Mice   Male
Conrad KL, 2011   49 d ays   Mice   Male
Knuth ED, 2007   7 d ays   Rats   Female
Hermes G, 2011   70 d ays   Rats   Female
Knuth ED, 2007   7 d ays   Rats   Male
Blakley G, 2006   14 days   Rats   Male
Das SK, 2015   14 days   Rats   Male
Djordjevic J, 2012   21 d ays   Rats   Male
Lukkes JL, 2009   21 d ays   Rats   Male
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oFig. 7. lusive (Griebel and Holmes, 2013; Perez-Caballero et al., 2014).
iven the inhibitors’ clinical use, it is paradoxical that Htt knock-
uts have elevated anxiety relative to controls (0.57 g) and thatAnxiolytic Anxiogenic
inued)Htt overexpression dramatically reduces rodent anxiety (−0.94 g).
The reason for this drug/gene incongruence is not clear. In some
cases, the authors of the primary Htt knockout studies have not
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Hedges’ g
Intervention NC NT Anxiolytic Anxiogenic
A
Fig. 8. Species differences in ARDEB. (A) Contrasts of mice and rats naive defence behaviors in three different assays. Upper panel shows the means of proportion of time
spent  in the exposed region, categorized by assay type and species. Each point is the mean value of an experiment. The lower panel shows the contrast means and conﬁdence















opecies (green = mice, orange = rats). Each mean effect size is represented by the c
orizontal axis is Hedges’ g, the standard deviation change relative to control ani
nterpretation of the references to color in this ﬁgure legend, the reader is referred 
iscussed it (Carroll et al., 2007; Kalueff et al., 2007a; Moya et al.,
011; Schipper et al., 2011). Other authors have remarked that the
nderlying reason remains unclear (Holmes et al., 2003b; Lira et al.,
003) or have called the validity of ARDEB assays into doubt (Pang
t al., 2011). As both genetic knockouts and SSRIs are expected
o produce monotonic, systemic reductions of SERT function, this
ncongruence is not easily explained by models of serotonin con-
icting action that invoke distinct 5-HT circuits in the brain with
pposing effects on defense (Deakin and Graeff, 1991). Others have
roposed two explanatory hypotheses. The ﬁrst is that increased
nxiety arises from developmental alterations present in Htt knock-
uts not present in chronically drug-treated animals (Holmes et al., vertices of diamond; the outer vertices indicate the 95% conﬁdence interval. The
NC and NT indicate control and treatment animal sample sizes respectively. (For
 web  version of this article.)
2003b; Olivier et al., 2008; Zhao et al., 2006). This hypothesis could
be tested with conditional knockdown models, i.e. in animals with
Htt only deleted at the adult stage. While systematic review of
PubMed and EMBASE did not identify any published reports of post-
developmental Htt knockout experiments (e.g., using ﬂoxed Htt),
researchers have analyzed the anxiety-related effects of condition-
ally ablating the Pet-1 gene. Pet-1 is a transcription factor with an
expression range that overlaps closely with the expression of Htt.
In mice with Pet-1 removed in adulthood, mRNA levels of Htt are
substantially reduced (Liu et al., 2010). Like Htt knockouts, these
mice show increased anxiety-like behaviors in multiple ARDEB
assays (Liu et al., 2010), eroding conﬁdence in the developmental
F. Mohammad et al. / Neuroscience and Biobehavioral Reviews 68 (2016) 504–529 521
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Htr1a - OE
Fig. 9. Summary effect sizes of all meta-analyses. (A) The weighted mean effect sizes of all 10 interventions are shown here. Color indicates direction (green = anxiolytic,
red  = anxiogenic) and statistical signiﬁcance (grey = statistically non-signiﬁcant). The diamonds for the diazepam, social isolation, and Htt KO meta-analyses represent the
summary effect sizes after trim-and-ﬁll bias correction. Each mean effect size is represented by the central vertices of a diamond; the outer vertices indicate the 95% conﬁdence






















seport  ARDEB changes with 59% concordance. (C) Method comparison of OF and LD
omparion of OF and EPM shows that there is no concordance between the two m
eferred to the web  version of this article.)
lteration hypothesis. A second hypothesis to explain the Htt/SSRI
aradox is that there is a J-shaped relationship between Htt func-
ion and anxiety, i.e., both wild-type and knockout animals would
ave higher anxiety relative to animals with intermediate function
Olivier et al., 2008). The SSRI/knockout paradox is also observed
n depression assays, though interfering RNA knockdown of Htt in
dult mice reduced the forced swim test measure of depression
N = 10, 10) (Thakker et al., 2005).
. Conclusions
This study conﬁrms that diazepam, two environmental stressors
nd three genes inﬂuence rodent anxiety as measured by defense
ehavior assays. These anxiety-related interventions (diazepam,
tr1a gene knockout, Htt gene knockout, Htt gene overexpres-
ion, acute pain, restraint and Crhr1 gene knockout) can be used as
eference manipulations when establishing other anxiety models.
he rodent anxiety literature is affected by publication bias that
mpliﬁes effect sizes. For the panel of ten interventions, there is
trong EPM-LD and OF-LD ARDEB assay concordance, but EPM and
F did not reproduce each other. The meta-analytic results bring
everal preclinical-clinical incongruencies into sharp relief: thes that the two methods reports ARDEB changes with 60% concordance. (D) Method
s. (For interpretation of the references to color in this ﬁgure legend, the reader is
weakness of Htr1a overexpression contrasting with the clinical use
of azapirones, the potently anxiogenic Crhr1 knockout contrasting
with the clinical failure of CRHR1 antagonists, and the anxiogenic
SERT knockout contrasting with the clinical use of SSRIs as anxi-
olytic drugs. Meta-analysis has the ability to aggregate information
and resolve discordance in the primary literature, something of
particularly use to behavioral neuroscience where most primary
articles describe experiments with poor precision (Button et al.,
2013). Precise estimation of effect magnitudes (Claridge-Chang and
Assam, 2016) is important both to better understand animal model
strengths/weaknesses and to improve the ability of preclinical
studies to guide clinical investigation. The formation of multi-lab
consortia to coordinate the examination of important hypothe-
sized anxiety factors would be one promising way  to increase the
reliability of rodent anxiety data (Button et al., 2013). New, auto-
mated methods of behavioral imaging will also play a role in better
preclinical models (Schaefer and Claridge-Chang, 2012). Another
possibility would be to use small animal models (worms, ﬂies, and
zebraﬁsh) that allow large sample sizes and powerful genetic tools
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